Navigation Links
FDA Approves New Treatment for Type 2 Diabetes
Date:5/2/2011

SILVER SPRING, Md., May 2, 2011 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today approved Tradjenta (linagliptin) tablets, used with diet and exercise, to improve blood glucose control in adults with Type 2 diabetes.

(Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO)

People with Type 2 diabetes do not produce or respond normally to insulin, a hormone that regulates the amount of glucose in the blood. Over time, high blood glucose levels can increase the risk for serious complications, including heart disease, blindness, and nerve and kidney damage.

"This approval provides another treatment option for the millions of Americans with Type 2 diabetes," said Mary Parks, M.D., director of the Division of Metabolism and Endocrinology Products in the FDA's Center for Drug Evaluation and Research. "It is effective when used alone or when added to existing treatment regimens."

Type 2 diabetes is the most common form of the disease, affecting between 90 percent and 95 percent of the 24 million people in the United States with diabetes. Tradjenta increases the level of hormones that stimulate the release of insulin after a meal by blocking the enzyme dipeptidyl peptidase-4 or DPP-4, which leads to better blood glucose control.

Tradjenta was demonstrated to be safe and effective in eight double-blind, placebo-controlled clinical studies involving about 3,800 patients with Type 2 diabetes. The studies showed improvement in blood glucose control compared with placebo.

Tradjenta has been studied as a stand-alone therapy and in combination with other Type 2 diabetes therapies including metformin, glimepiride, and pioglitazone. Tradjenta has not been studied in combination with insulin, and should not be used to treat people with Type 1 diabetes or in those who have increased ketones in their blood or urine (diabetic ketoacidosis).

Tradjenta will be dispensed with an FDA-approved Patient Package Insert that explains the drug's uses and risks. The most common side effects of Tradjenta are upper respiratory infection, stuffy or runny nose, sore throat, muscle pain, and headache.

Tradjenta is marketed by Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, Conn., and Indianapolis-based Eli Lilly Co.

For more information:

Type 2 Diabetes

http://www.nlm.nih.gov/medlineplus/ency/article/000313.htm

Approved Drugs: Questions and Answers

http://www.fda.gov/Drugs/ResourcesForYou/Consumers/ucm054420.htm

Media Inquiries: Morgan Liscinsky, 301-796-0397; morgan.liscinsky@fda.hhs.gov
Consumer Inquiries: 888-INFO-FDA


'/>"/>
SOURCE U.S. Food and Drug Administration
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. FDA Approves Zytiga for Late-Stage Prostate Cancer
2. FDA Approves Updated, Clarified Indication for Use for iFuse Implant System®
3. FDA Approves Lamictal®XR™ (Lamotrigine) for Conversion to Monotherapy for Treatment of Partial Seizures in Appropriate Patients
4. FDA Approves the First Vaccine to Prevent Meningococcal Disease in Infants and Toddlers
5. FDA Approves Actemra to Treat Rare Form of Juvenile Arthritis
6. FDA Approves New Medical Device for Form of Brain Cancer
7. FDA Approves the NovoTTF-100A System for the Treatment of Patients With Recurrent Glioblastoma Multiforme (GBM) Brain Tumors
8. FDA Approves Horizant To Treat Restless Legs Syndrome
9. FDA Approves New Treatment for Rare Form of Thyroid Cancer
10. FDA Approves Special Protocol Assessment for Phase 3 Trial of Polaris Groups Cancer Therapeutic, ADI-PEG 20, in the Treatment of Hepatocellular Carcinoma
11. FDA Approves Hyperopia Application for the MEL 80 Excimer Laser from Carl Zeiss Meditec
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2016)... , May 5, 2016 ... addition of the  "Europe Thalassaemia Market and ... their offering.       (Logo: ... Europe Thalassaemia Market and Competitive Landscape Highlights ... pipeline products, Thalassaemia epidemiology, Thalassaemia market valuations ...
(Date:5/4/2016)... Holdings (NYSE: CODI ) ("CODI," "we," "our" ... businesses, announced today its consolidated operating results for the ... Quarter 2016 Highlights , Generated Cash Flow Available ... $13.6 million for the first quarter of 2016; ... first quarter of 2016; , Paid a first ...
(Date:5/4/2016)...  It,s time for an upgrade. There are many medical recorders on the market ... the illustrious DVMAXX HD  offers unparalleled connectivity and functionality.  Ampronix  is a renowned ... manufacturer of innovative technology.  Photo - http://photos.prnewswire.com/prnh/20160503/363416 ... ... ...
Breaking Medicine Technology:
(Date:5/5/2016)... ... May 05, 2016 , ... Einstein Medical is proud to ... the latest news and commentary at the 2016 ASCRS/ASOA Symposium and Congress, which takes ... Society of Cataract and Refractive Surgery and the American Society of Ophthalmic Administrations will ...
(Date:5/5/2016)... ... May 05, 2016 , ... Phycologia – ... (UV-A) for photosynthesis, researchers Juntian Xu and Kunshan Gao tested the magnitude of ... observed that when photosynthetically active radiation (i.e. the white light in our visible ...
(Date:5/5/2016)... ... May 05, 2016 , ... Every year 220 ... heartfelt wishes of these children. The wishes provide hope and motivation through ... CEO of Make-A-Wish Mississippi, Brent Wilson said, “In 2016, the organization will grant ...
(Date:5/5/2016)... ... 05, 2016 , ... Long Island’s fastest growing comprehensive eye care provider, ... surgeon, Kathleen Van Valkenburg, MD as part of their ongoing effort to increase ophthalmic ... and managing partner of North Shore Eye Care. , “We are extremely proud ...
(Date:5/5/2016)... ... ... TIME for Kids and The ZAC Foundation – a national leader in drowning ... million children with important water safety messages before summer break begins. , ... in children one to 6 years of age. TIME for Kids and The ...
Breaking Medicine News(10 mins):